Axitinib for the Management of Metastatic Renal Cell Carcinoma

Drugs in R and D- United Kingdom

doi 10.2165/11591240-000000000-00000

Full Text

Abstract

Available in

Categories

Pharmacology

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Pharmacoeconomic Evaluation of Axitinib Introduction in Metastatic Renal Cell Carcinoma Treatment Scheme

Pharmacoeconomics: theory and practice
2014English

Axitinib Plus Pembrolizumab Is Effective in Renal Cell Carcinoma

Cancer Discovery
Oncology
2018English

Outcomes of Multi-Disciplinary Management of Metastatic Renal Cell Carcinoma

Cureus
2019English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Results of Surgical Management of Renal Cell Carcinoma Metastatic to the Pancreas

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2015English

Renal Cell Carcinoma Metastatic to the Scalp

Rare Tumors
OncologyHistology
2016English

Extended Progression-Free Survival of Renal Cell Carcinoma With Axitinib: Case Report

Journal of Urology and Renal Diseases
2018English

Nonablative Hematopoietic Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma

Bone Marrow Transplantation
TransplantationHematology
2002English

Metastatic Polyp of the Gallbladder From Renal Cell Carcinoma

HPB
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy